Literature DB >> 9788355

Neural network-based prediction of candidate T-cell epitopes.

M C Honeyman1, V Brusic, N L Stone, L C Harrison.   

Abstract

Activation of T cells requires recognition by T-cell receptors of specific peptides bound to major histocompatibility complex (MHC) molecules on the surface of either antigen-presenting or target cells. These peptides, T-cell epitopes, have potential therapeutic applications, such as for use as vaccines. Their identification, however, usually requires that multiple overlapping synthetic peptides encompassing a protein antigen be assayed, which in humans, is limited by volume of donor blood. T-cell epitopes are a subset of peptides that bind to MHC molecules. We use an artificial neural network (ANN) model trained to predict peptides that bind to the MHC class II molecule HLA-DR4(*0401). Binding prediction facilitates identification of T-cell epitopes in tyrosine phosphatase IA-2, an autoantigen in DR4-associated type1 diabetes. Synthetic peptides encompassing IA-2 were tested experimentally for DR4 binding and T-cell proliferation in humans at risk for diabetes. ANN-based binding prediction was sensitive and specific, and reduced the number of peptides required for T-cell assay by more than half, with only a minor loss of epitopes. This strategy could expedite identification of candidate T-cell epitopes in diverse diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788355     DOI: 10.1038/nbt1098-966

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  31 in total

1.  Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles.

Authors:  Pedro A Reche; John-Paul Glutting; Hong Zhang; Ellis L Reinherz
Journal:  Immunogenetics       Date:  2004-09-03       Impact factor: 2.846

2.  MHC-BPS: MHC-binder prediction server for identifying peptides of flexible lengths from sequence-derived physicochemical properties.

Authors:  Juan Cui; Lian Yi Han; Hong Huang Lin; Zhi Qun Tang; Li Jiang; Zhi Wei Cao; Yu Zong Chen
Journal:  Immunogenetics       Date:  2006-07-11       Impact factor: 2.846

3.  A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes.

Authors:  Manoj Bhasin; G P S Raghava
Journal:  J Biosci       Date:  2007-01       Impact factor: 1.826

Review 4.  Advances in the study of HLA-restricted epitope vaccines.

Authors:  Lingxiao Zhao; Min Zhang; Hua Cong
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

5.  Efficacy of HLA-DRB1∗03:01 and H2E transgenic mouse strains to correlate pathogenic thyroglobulin epitopes for autoimmune thyroiditis.

Authors:  Yi-chi M Kong; Nicholas K Brown; Jeffrey C Flynn; Daniel J McCormick; Vladimir Brusic; Gerald P Morris; Chella S David
Journal:  J Autoimmun       Date:  2011-06-17       Impact factor: 7.094

6.  TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes.

Authors:  Diego Chowell; Sri Krishna; Pablo D Becker; Clément Cocita; Jack Shu; Xuefang Tan; Philip D Greenberg; Linda S Klavinskis; Joseph N Blattman; Karen S Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

7.  Prediction of MHC binding peptide using Gibbs motif sampler, weight matrix and artificial neural network.

Authors:  Satarudra Prakash Singh; Bhartendu Nath Mishra
Journal:  Bioinformation       Date:  2008-12-06

8.  Proteomics in Vaccinology and Immunobiology: An Informatics Perspective of the Immunone.

Authors:  Irini A. Doytchinova; Paul Taylor; Darren R. Flower
Journal:  J Biomed Biotechnol       Date:  2003

9.  VitAL: Viterbi algorithm for de novo peptide design.

Authors:  E Besray Unal; Attila Gursoy; Burak Erman
Journal:  PLoS One       Date:  2010-06-02       Impact factor: 3.240

Review 10.  Tumor neoantigens: building a framework for personalized cancer immunotherapy.

Authors:  Matthew M Gubin; Maxim N Artyomov; Elaine R Mardis; Robert D Schreiber
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.